Dexcom’s newly FDA-cleared G7 15-Day CGM system marks a major leap forward in diabetes technology, combining longer wear, improved accuracy, and unmatched ease of use.

Users should always confirm readings on the Dexcom G7 app or receiver before making treatment decisions. ¶Compared to a prior generation Dexcom CGM System.

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

About the Dexcom U.S. G5 Mobile Launch The G5 Mobile system is anticipated to begin shipping in late September 2015.

Dexcom is working closely with its insulin pump partners to ensure that Dexcom G7 15 Day will be compatible with automated insulin delivery systems upon launch.

TORONTO, July 16, 2020 /CNW/ - Last week, Health Canada temporarily authorized the adjunctive use of the Dexcom G6 Continuous Glucose Monitoring (CGM) system by pregnant women with Type 1, Type 2, or ...